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Abstract
Background: The early events underlying Alzheimer's disease (AD) remain uncertain, although
environmental factors may be involved. Work in this laboratory has shown that the combination
of herpes simplex virus type 1 (HSV1) in brain and carriage of the APOE-ε4 allele of the APOE gene
strongly increases the risk of developing AD. The development of AD is thought to involve
abnormal aggregation or deposition of a 39–43 amino acid protein – β amyloid (Aβ) – within the
brain. This is cleaved from the much larger transmembranal protein 'amyloid precursor protein'
(APP). Any agent able to interfere directly with Aβ or APP metabolism may therefore have the
capacity to contribute towards AD. One recent report showed that certain HSV1 glycoprotein
peptides may aggregate like Aβ; a second study described a role for APP in transport of virus in
squid axons. However to date the effects of acute herpesvirus infection on metabolism of APP in
human neuronal-type cells have not been investigated. In order to find if HSV1 directly affects APP
and its degradation, we have examined this protein from human neuroblastoma cells (normal and
transfected with APP 695) infected with the virus, using Western blotting.
Results: We have found that acute HSV1 (and also HSV2) infection rapidly reduces full length APP
levels – as might be expected – yet surprisingly markedly increases levels of a novel C-terminal
fragment of APP of about 55 kDa. This band was not increased in cells treated with the protein
synthesis inhibitor cycloheximide
Conclusion: Herpes virus infection leads to rapid loss of full length APP from cells, yet also causes
increased levels of a novel 55 kDa C-terminal APP fragment. These data suggest that infection can
directly alter the processing of a transmembranal protein intimately linked to the aetiology of AD.
Background
The key events which initiate Alzheimer's disease (AD)
remain unclear, though environmental factors have been
shown to be involved [1]. The two main neuropathologi-
cal features of AD – senile plaques (SP) and neurofibril-
lary tangles – occur also in the normal elderly. AD may be
triggered when the numbers of these features increase to
abnormal levels. Although there is much evidence sup-
porting the involvement of one or both of these structures
in the disease process, it is unclear whether they are
involved directly, what processes underlie their forma-
tion, and why their numbers rise during the development
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of AD. However, any environmental stimulus capable of
leading to production of the abnormal proteins which
make up these structures might thereby contribute to the
occurrence of AD.
β-amyloid protein (Aβ) is the major proteinaceous com-
ponent of senile plaques, and the abnormal deposition of
aggregates of this protein is thought to give rise to SP for-
mation. Aβ comprises a sequence of 39–43 amino acids
and is formed by cleavage from the much longer amyloid
precursor protein (APP), first by β-secretase then by γ-
secretase. Generation of Aβ may lead eventually to the
development of neurotoxic SPs, which themselves cause
further tissue damage and SP generation, or alternatively
to the production of small neurotoxic Aβ assemblies,
which may be the most damaging form of Aβ [2]. What-
ever the mechanism leading to neuronal damage after Aβ
generation, any agent which interferes with amyloid sys-
tems may thereby contribute to the development of AD.
Studies of the possible role of pathogens in AD were made
possible in the early 1990s by the development of PCR,
allowing detection of low levels of viral or bacterial DNA
within human brain tissues. However very few investiga-
tors have undertaken such studies, and most work has
focused on herpes simplex virus type 1 (HSV1). A causal
role for this virus in triggering AD was suggested by
Itzhaki et al., who found that the risk of developing AD
associated with carriage of an APOE-ε4 allele depends on
the presence of latent HSV1 in the brain [3,4]. Coupled
with the finding here of a higher APOE-ε4 allele frequency
amongst individuals who suffer damage after HSV1 reac-
tivation in the periphery – seen as cold sores – this indi-
rectly supports a role for HSV1, perhaps acting with other
pathogens [5], as a key environmental contributor to AD
[3,4].
Recent epidemiological studies support the involvement
of a pathogen in AD: cognitive function in AD patients
declines for at least 2 months after a systemic infection
[6]; cognitive decline in elderly cardiovascular patients
correlates with viral burden [7]. These could be explained
by systemic infection causing brain inflammation which,
in turn, leads to reactivation of latent HSV1 – and conse-
quent further damage in the CNS. Consistently, in mid-
dle-aged controls, very few of whom would harbour HSV1
in brain [8], no cognitive decline occurs after systemic
infection [9]. Enhancement of damage in brain, due to the
presence of an infectious agent, is supported by the find-
ing that inflammation in brain caused by lipopolysaccha-
ride is augmented in pre-clinical prion-infected mice [10].
One mechanism by which HSV1 might contribute to AD
was suggested by the detection of a sequence homology
between Aβ and the HSV1 glycoprotein B (gB), a viral coat
protein which is involved in attachment of the virus to
cells, and by the finding that synthetic peptides derived
from gB can give rise to Aβ-like aggregates. The authors
suggested that such viral proteins might act as a seed for
amyloid plaque formation [11]. Another way in which
infection might affect amyloid biochemistry is suggested
by studies demonstrating that Aβ or APP are upregulated
in response to a wide range of injurious stimuli, including
head injury [12], stroke [13] or HIV infection [14].
Increased expression of APP – though not of the related
protein amyloid precursor-like protein 2 (APLP2) – has
been reported in cutaneous wound repair [15]. APP foci
colocalise with sites of opportunistic infection in HIV
dementia patients, including sites of herpes virus
(cytomegalovirus) infection [16]. Another type of APP-
HSV1 interaction has been demonstrated in axonal trans-
port: APP was found to be present in HSV1 particles and
it was suggested that this could lead to alterations in loca-
tion and processing of APP at the nerve terminal [17]
causing synaptic and neuronal dysfunction.
No studies have been made on HSV1 effects on APP or Aβ
in cells in culture. Here we describe the first to investigate
whether levels of APP and its metabolites are affected by
HSV1 infection, using human neuronal-type cells in
culture.
Results and discussion
We carried out initial experiments on SHSY5Y cells to
determine the level of HSV1 needed to ensure that on
inoculation most cells were infected. We then examined
levels of APP in lysates prepared from the cells 6 h after
infection with this dose of HSV1. Western blots stained
with anti C-terminal APP antibody (Fig. 1A) revealed, as
expected, various full-length APP bands in uninfected
cells corresponding to the three main isoforms in multiple
glycosylation states. Deglycosylation experiments have
shown that the lower single band (100 kDa) is immature
APP695, that the doublet above this (approx molecular
weight 115 kDa) is mature APP695 and immature
APP751/APP770 and that the highest molecular weight
group (approx. 125 to 135 kDa) comprises a mixture of
mature APP751 and mature APP770 (Parkin et al., unpub-
lished observations).
The intensity of these bands decreased appreciably in cells
harvested only 3 h after inoculation with HSV1, as did
those from cells treated with the protein synthesis inhibi-
tor cycloheximide. This decline after infection may reflect
loss of ability of the cells to generate new APP due simply
to virus-induced shut-down of protein synthesis [18].
Of particular interest was the relative intensity of a 55 kDa
band, again apparent after C-terminal APP antibody stain-
ing. This band was similarly intense in control-treated andBMC Microbiology 2005, 5:48 http://www.biomedcentral.com/1471-2180/5/48
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Effect of HSV1 infection on APP processing in SHSY5Y cells Figure 1
Effect of HSV1 infection on APP processing in SHSY5Y cells. (A) SHSY5Y human neuroblastoma cells were either 
untreated (cont), infected with herpes simplex virus type 1 (HSV1), or treated with the protein synthesis inhibitor cyclohex-
imide (CH), then incubated for a further 6 h. Cell lysates were subjected to Western blot analysis, using an anti-C-terminal 
APP antibody (Sigma Aldrich A8717) at 1:4000 dilution. Each lane contains cell lysate prepared from a single flask (two flasks 
were used per treatment). Several full-length APP bands are clearly visible. Arrows indicate the band intensified by HSV1 infec-
tion. (B) Quantification of 55 kDa band in control (cont), cycloheximide-treated (CH), or HSV1 infected cells, assessed using 
Syngene GeneTools software. Values show average band height from five independent experiments for cells treated for 6 h, 
each involving two or four separately processed flasks. Bars show standard deviation. Treatments resulting in values signifi-
cantly different from control are marked * (indicates p < 0.002; ANOVA). (C) Effect of time period after inoculation with virus 
on height of 55 kDa band. SHSY5Y human neuroblastoma cells were either untreated (cont), infected with HSV1, or treated 
with cycloheximide (CH), then incubated for a further 3, 6 or 9 h. Cell lysates were analysed by Western blotting as in Fig 1A. 
Arrows indicate the band intensified by HSV1 infection.BMC Microbiology 2005, 5:48 http://www.biomedcentral.com/1471-2180/5/48
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cycloheximide-treated cells, but had far greater intensity
after HSV1 infection. This increase in HSV1-infected cells
alone was highly reproducible, occurring in many experi-
ments, each carried out independently, from the infection
to the blotting stage. Band intensity for cells treated for 6
hours was quantified using Syngene Genetools software
and averaged over five such experiments is shown in Fig-
ure 1B; value for HSV1-infected cells was significantly dif-
ferent from control, being elevated by 124% (95%CI 101
– 148%; p < 0.002), whereas that for cycloheximide-
treated cells was similar to the control value.
To exclude the possibility that the band reflected synthesis
of a viral protein which cross-reacts non-specifically with
the antibody, we immunostained blots produced from
gels of viral proteins from our HSV1 preparations. No evi-
dence for any cross-reaction of the Sigma C-terminal APP
antibody with these proteins could be found, suggesting
that the strengthened band was cell-derived (results not
shown). This result does not preclude any cross-reactivity
with an ICP, as the latter would not be present within vir-
ions, but the presence of the 55 kDa protein in uninfected
cells, and also, at a higher level, in APP-transfected cells
(see below), strongly supports a cellular, non-viral origin
of the protein. Interestingly, APP has been detected in
HSV1 virions by Western blotting [17], but this probably
reflects the authors' usage of a much more concentrated
and purified virus preparation than that of the inoculate
we use for infecting cells.
We next examined the influence of duration of infection
on these viral-induced changes (Fig. 1C). As anticipated,
with increasing duration before harvesting, the depletion
of APP became more pronounced (this was found also
with cycloheximide treatment); in contrast, the intensity
of the C-terminal 55 kDa fragment seen in the infected
cells was not higher than in uninfected cells at 3 hr, but
increased at 6 hr and 9 hr. However there was minimal
further change as incubation increased to 24 hr (not
shown). This result also was found to be reproducible on
repeating the experiment several times from infection to
blotting. It suggests that infection prevents synthesis of
APP, leading to its gradual depletion, but causes also the
abnormal accumulation of the 55 kDa fragment due, pre-
sumably, to a decrease in degradation of the latter. How-
ever, for longer incubation times, we cannot exclude the
possibility of sequestration of some APP within newly
synthesised viral particles, as reported elsewhere [17],
which might reduce the amount of APP in the virus-free
cell lysates used for the preparation of cell proteins.
We repeated these experiments with herpes simplex virus
type 2 (HSV2), to see whether these effects were specific to
HSV1. Fig. 2 shows that very similar findings were
obtained, with 55 kDa band intensity for HSV2-infected
cells 9 hr after infection being 101% greater than that for
control cells (95%CI 94 – 107%; p < 0.005) suggesting
that this phenomenon is not uniquely associated with
HSV1 infection.
On the assumption that a corresponding N-terminal frag-
ment of approximately similar size to that of the 55 kDa
C-terminal fragment would be produced as a result of this
abnormal processing (the size of APP being 110 kDa to
135 kDa), we probed our blots with the Sigma N-terminal
antibody (Fig 3A). However we found no clear evidence
for an increased amount of an N-terminal fragment of
around this size after infection. Possibly, such a fragment
would be either degraded or released into the cell culture
medium, thus precluding its detection here.
To confirm further that the C-terminal fragment is derived
from APP (and not for example from an APLP, i.e. of a
type of protein related to APP, though with a less clear
involvement in AD) we obtained human SYSY5Y cells
that had been transfected with a human APP gene
(APP695), and which over-express APP. We stained blots
of proteins from non-transfected, APP transfected, and
mock-transfected (i.e. with vector alone) cells with the C-
terminal antibody, and found the 55 kDa band in all three
cases, though its intensity was greater in the APP trans-
fected cells alone (see Fig. 3B). This indicates that the 55
kDa fragment is indeed an APP product.
Effect of HSV2 infection on APP processing in SHSY5Y cells Figure 2
Effect of HSV2 infection on APP processing in 
SHSY5Y cells. SHSY5Y human neuroblastoma cells were 
either untreated (cont), infected with HSV2, or treated with 
cycloheximide (CH), then incubated for 9 h. Cell lysates 
were analysed by Western blotting as in Fig 1A. Arrows indi-
cate the band intensified by HSV2 infection.BMC Microbiology 2005, 5:48 http://www.biomedcentral.com/1471-2180/5/48
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Absence of N-terminal fragment and confirmation that 55 kDa fragment is derived from APP Figure 3
Absence of N-terminal fragment and confirmation that 55 kDa fragment is derived from APP. (A) Staining with 
antibody to N-terminal APP. SHSY5Y human neuroblastoma cells were either untreated (cont) or infected with HSV1, then 
incubated for a further 6 h. Cell lysates were analysed by Western blotting using an anti-N-terminal APP antibody 22C11. No 
evidence for increase in an N-terminal fragment of the expected M Wt. was observed, suggesting the latter may be metabo-
lised further or secreted. (B) Strengthening of 55 kDa band in uninfected APP-transfected SHSY5Y cells. Normal SHSY5Y 
human neuroblastoma cells, mock-transfected SHSY5Y cells (mTf) or APP695 transfected cells (APP Tf) were uninfected prior 
to harvest. In addition normal SHSY5Y cells which had been infected with HSV1 (lane labelled HSV1) for 6 h were also pre-
pared, to allow position of the HSV1-senstive 55 kDa band to be clearly identified. Cell lysates were subjected to Western blot 
analysis, and probed with an anti-C-terminal APP antibody (Sigma Aldrich A8717) at 1:4000 dilution. Arrows indicate the posi-
tion of the band intensified after HSV1 infection. The intensity of full-length APP bands was appreciably greater than those in 
the non-transfected cells. In addition the intensity of several smaller bands was also greater than the intensity of the same 
bands in the mock-transfected (mTf) or normal SHSY5Y (cont), including a band at the same position as the band intensified on 
HSV1 infection of normal SHSY5Y cells (marked by the arrows), suggested this band is genuinely derived from APP.BMC Microbiology 2005, 5:48 http://www.biomedcentral.com/1471-2180/5/48
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Conclusion
Infection of neuronal cells by HSV1 is known to cause
rapid shutoff of protein synthesis prior to viral replication
[19]. This is mediated by the virion host shut-off (vhs)
protein, which destabilises cellular mRNAs causing them
to be degraded. Consequently, and unsurprisingly, tran-
scription of the gene(s) for APP would cease, as would its
synthesis and that of other proteins. Our finding that lev-
els of full length APP decline rapidly in infected cells and
in cells treated with cycloheximide, suggest that in both
cases turnover of full length APP is rapid.
The surprising increase in amount of the 55 kDa C-termi-
nal APP fragment in infected cells shows that processing
of APP as well as its synthesis is affected by HSV1, that this
occurs within 6 h of infection, and that the level increases
with time after infection up to at least 9 h. The size of this
fragment and its staining with C-terminal antibody indi-
cate that it includes the region of APP which contains Aβ.
The possibility that the 55 kDa band derives from an APLP
or merely reflects a non-specific reaction of the APP anti-
body with a viral protein or ICP is unlikely. Our viral prep-
arations did not cross-react with this antibody, and at the
time when this band begins to increase in intensity (6 h)
the majority of ICPs would have already appeared. Fur-
thermore the 55 kDa band is present (at lower levels) in
cells not infected with virus. Also, cells transfected with
APP (though not mock-transfected cells) have a higher
level of this 55 kDa fragment than do untransfected unin-
fected cells.
The fact that the mock-transfected and cycloheximide-
treated cells do not show any intensification of the 55 kDa
band suggests that this phenomenon is not due merely to
a non-specific stress response, but occurs in response to
infection, although the increase in the fragment after
HSV2 infection shows the effect is not specific for HSV1
infection alone. Interestingly, infection of human brain
microvascular endothelial cells with Chlamydia pneumonia
(Cpn) may increase the intensity of a similar 55 kDa C-ter-
minal APP band (personal communication, Professor
Brian Balin, PA, USA). Thus, increased production of this
fragment may be a general response to infection.
Currently HSV1 is the only virus that has been shown to
be present in brain of most elderly humans [20] – and
may be present as a whole functional genome [21]. Active
infection of brain cells with other agents might lead to the
same APP effects, but until or unless they are shown to be
present, they can not be proposed as possible factors in
AD. The situation regarding presence or absence of the
bacterium Cpn in brain appears unresolved, although a
direct role for Cpn in amyloid systems is supported by
recent studies in mice showing amyloid deposition in
animals intracerebrally infected with Cpn [22]. Confirma-
tion of Cpn presence would support the possibility that,
as with HSV1, the increased level of the 55 kDa fragment
that it causes might contribute to AD.
The low levels of Aβ secreted by SHSY5Y cells preclude our
examining at present the effects of HSV1 infection on lev-
els of Aβ in cell culture models. Eventual identification of
those components of Aβ protein systems which are altered
by active viral infection will clarify whether pathogens
such as HSV1 can contribute directly to the development
of AD neuropathology.
We report here that levels of full length APP rapidly
decline in human neuronal type cells acutely infected with
either HSV1 or HSV2. Also, the amount of a C-terminal 55
kDa APP fragment which contains the Aβ sequence
appears to increase rapidly in infected cells. The fragment
level is greater in (non-virally infected) SHSY5Y cells
transfected with APP695, suggesting that it is almost cer-
tainly derived from APP rather than from APLP. The
fragment may increase as part of a host defence mecha-
nism, and/or it might lead to increased generation of Aβ.
We are now investigating whether the latter possibility is
correct.
Methods
Cell culture
Human neuroblastoma (SHSY5Y) cells were maintained
in Eagle's minimum essential medium (EMEM) supple-
mented with 10% (v/v) foetal bovine serum (FBS), 2% (v/
v) glutamine and 1% (v/v) penicillin/streptomycin (10%
medium), hereafter referred to as growth medium. Cells
were incubated at 37°C in a humidified atmosphere of
5% carbon dioxide.
SHSY5Y neuroblastoma cells over-expressing APP695 were
prepared by double blunt end ligation of the human
APP695 sequence into the BstXI site of pIREShyg (BD Bio-
sciences Clontech, California, USA). For stable transfec-
tions 30 µg of DNA was introduced to cells by
electroporation and selection was performed in normal
growth medium containing 100 µg ml-1 hygromycin B
selection antibiotic (Gibco BRL, Paisley, UK). 'Mock-
transfected' cells were stably transfected with the empty
pIREShyg vector.
HSV1 (strain SC16) stocks were prepared from a primary
stock kindly provided by Prof. Roy Jennings (Department
of Virology, University of Sheffield), using Vero cells as
host. Herpes simplex virus type 2 stocks were prepared
from a clinical isolate kindly provided by Prof Anthony
Hart (University of Liverpool) as for HSV1, using HEp2a
cells. In both cases, confluent cell monolayers were inoc-
ulated at high multiplicities of infection (>10 plaque-BMC Microbiology 2005, 5:48 http://www.biomedcentral.com/1471-2180/5/48
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forming units (pfu) per cell) with virus suspended in
growth medium containing only 1% FBS. Once cyto-
pathic end point was reached (after about two days) virus
was harvested from medium and from cells disrupted by
low power sonication. Cellular debris was removed by
low speed centrifugation (1000 g, 10 min), and virus was
isolated by high speed centrifugation of the supernatant
(10000 g, 2 h, 4°C) using a Sorvall SS34 rotor. Virus-con-
taining pellets were suspended in PBS, and stored in aliq-
uots at -85°C; their infectivity was assessed by plaque
assay of serial dilutions. The virus preparations were
checked for bacterial sterility by inoculation into beef
heart agar plates and confirming the absence of bacterial
growth after incubation for several days at 37°C. For both
viruses three sequential passages were prepared, and only
passage 3 stocks used here.
SHSY5Y cells were seeded at a concentration of 8 million
cells per flask (T175) and incubated overnight. Prior to
infection, growth medium was discarded and cells were
then washed briefly 10 ml of PBS at 37°C. HSV1 (or in
some experiments HSV2) was introduced in 10 ml of
growth medium (containing only 0.5% serum), at 3 pfu/
cell. For controls, either 0.5% serum containing growth
medium alone or the latter containing cycloheximide at
10 µg/ml was used. After 1 hr incubation, the inoculating
medium (or control treatment) was removed, and 10 ml
of fresh 0.5% serum containing growth medium was
added, followed by further incubation for various times.
Protein extraction and Western blotting
Cells were harvested by removing medium, washing twice
with 10 ml PBS, and incubated in 1 mM EDTA (pH 7.4)
(in PBS) at room temperature for 10 min. The cell suspen-
sion was centrifuged (500 g, 5 min, 4°C), and the cell pel-
let was resuspended in 400 µl of homogenisation buffer
(0.5% Triton X-100 in PBS; 2 mM phenylmethylsulphlflu-
oride (PMSF); 100 µg/ml of aprotinin and 100 µg/ml leu-
peptin). Cell lysis was completed by sonication (MSE
sonicator, 4°C, 10 µm amplitude, 6 × 10 s).
After measuring the protein concentration of each lysate
(BCA protein assay; Pierce), samples were prepared for
polyacrylamide gel electrophoresis (PAGE) by mixing 60
µg of protein with 0.25 volume of ×5 Laemmli sample
buffer containing 25% β-mercaptoethanol, and boiling
for 5 min. Samples were subjected to electrophoresis on
10% SDS-PAGE gels and the proteins transferred to PVDF
membranes (Immobilin-P, Millipore) by Western
blotting.
Membranes were blocked for 1 h using 8% skimmed-
powdered milk in 0.5% Tween in TBS (TBST). The mem-
brane was then washed (this and subsequent washes
involved 5 separate 5 min washes in TBS) and then incu-
bated with primary antibody, diluted 1:4000 with TBS
(for 1 1/2 h). Primary antibodies used were anti-C-termi-
nal APP (Sigma; A8717), and the anti-N-terminal APP
antibody 22C11. After a further wash, membranes were
incubated with secondary antibody conjugated with per-
oxidase (Pierce) which had been diluted 1:1250 with 8%
milk in TBS for 1 h. After a final wash the membrane was
incubated with Supersignal West Pico Chemiluminescent
Substrate Kit (Pierce) for 10 min, and proteins were then
visualised by chemiluminescence using a gel documenta-
tion system (Syngene).
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